Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …

Cancer immunotherapy is now established as a powerful way to treat cancer. The recent
clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) …

Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous
melanoma, is largely unresponsive to checkpoint immunotherapy. Here, we interrogate the …

Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses
in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal …

Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …

Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce
durable responses in a substantial fraction of melanoma patients. We sought to determine …

Uveal melanoma represents∼ 85% of all ocular melanomas and up to 50% of patients
develop metastatic disease. Metastases are most frequently localised to the liver and, as few …

Immunotherapy is a promising treatment strategy for cancer that has recently shown
unprecedented survival benefits in selected patients. A number of immunomodulatory …

Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal
melanomas. These cancers represent 5% of all melanoma diagnoses in the United States …